2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
Titel:
2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
Auteur:
Llop-Guevara, A. Vladimirova, V. Schneeweiss, A. Villacampa, G. Karn, T. Zahm, D-M. Herencia-Ropero, A. Jank, P. van Mackelenbergh, M. Fasching, P.A. Marmé, F. Stickeler, E. Schem, C. Dienstmann, R. Florian, S. Nekljudova, V. Balmaña, J. Denkert, C. Loibl, S. Serra, V.